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Bleomycin-Induced Pneumonitis*
Stefan Sleijfer, MD, PhD
The cytotoxic agent bleomycin is feared for its induction of sometimes fatal pulmonary toxicity,
also known as bleomycin-induced pneumonitis (BIP). The central event in the development of
BIP is endothelial damage of the lung vasculature due to bleomycin-induced cytokines and free
radicals. Ultimately, BIP can progress in lung fibrosis. The diagnosis is established by a
combination of clinical symptoms, radiographic alterations, and pulmonary function test results,
while other disorders resembling BIP have to be excluded. Pulmonary function assessments most
suitable for detecting BIP are those reflecting lung volumes. The widely used transfer capacity of
the lungs for carbon monoxide appeared recently not to be specific when bleomycin is used in a
polychemotherapeutic regimen. There are no proven effective treatments for BIP in humans,
although corticosteroids are widely applied. When patients survive BIP, they almost always
recover completely with normalization of radiographic and pulmonary function abnormalities.
This review focuses on BIP, especially on the pathogenesis, risk factors, and its detection.
(CHEST 2001; 120:617–624)
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Abbreviations: BEP 5 bleomycin, etoposide, cisplatin; BIP 5 bleomycin-induced pneumonitis; BOOP 5 bronchiolitis
obliterans with organizing pneumonia; EP 5 etoposide, cisplatin; G-CSF 5 granulocyte-colony stimulating factor;
IL-interleukin; TGF 5 transforming growth factor; TLC 5 total lung capacity; Tlco 5 transfer capacity of the lungs for
carbon monoxide; TNF 5 tumor necrosis factor; VC 5 vital capacity
B leomycin is an antibiotic agent with antitumoractivity discovered by Umezewa et al1 in 1966
and was originally isolated from the fungus Strepto-
myces verticillus. It is commonly used as part of the
cytostatic treatment of several tumor types, such as
germ-cell tumors, lymphomas, Kaposi’s sarcoma,
cervical cancer, and squamous cell carcinomas of
head and neck.
Bleomycin exerts its antitumor effect by inducing
tumor cell death, while inhibition of tumor angio-
genesis may also be important.2 Its cytotoxicity oc-
curs by induction of free radicals. Bleomycin forms a
complex with Fe (II), which is subsequently oxidized
to Fe (III), resulting in reduction of oxygen to free
radicals. These free radicals cause DNA breaks
leading to cell death ultimately.3–5 Bleomycin can be
given by several routes: IV, IM, or subcutaneously; in
case of malignant effusion, it can be administered
intrapleurally or intraperitoneally. The elimination of
bleomycin is mainly by the kidneys; in the first 24 h
after its administration, approximately 60% of un-
changed drug is excreted.6 Furthermore, bleomycin
can be deactivated by the enzyme bleomycin hydro-
lase, which can be found predominantly in the liver,
spleen, bone marrow, and intestine.7
The application of bleomycin is featured by the
occurrence of sometimes fatal side effects. Due to
the lack of the bleomycin-inactivating enzyme, bleo-
mycin hydrolase, in the lungs and the skin,8 bleomy-
cin-induced toxicity occurs predominantly in these
organs. Directly after its administration, the occur-
rence of fever, chills, and sometimes hypotension is
well known.9,10 Other side effects are dermal hyper-
pigmentation and fibrosis, stomatitis, and fatigue.11
The most feared and dose-limiting side effect of
bleomycin is its induction of pulmonary toxicity.
Several distinct pulmonary syndromes have been
associated with the use of bleomycin, such as bron-
chiolitis obliterans with organizing pneumonia
(BOOP),12 eosinophilic hypersensitivity,13 and, most
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commonly, interstitial pneumonitis, which ultimately
may progress into fibrosis. The latter, bleomycin-
induced pneumonitis (BIP), occurs in 0 to 46% of
the patients treated with bleomycin-containing che-
motherapy, depending on the criteria used for the
diagnosis.14–18 The mortality of patients with BIP has
been reported to be approximately 3% of all patients
treated with bleomycin.18,19 This review will focus on
BIP, especially on its pathogenesis, risk factors, and
the detection by pulmonary function assessments.
Clinical Features
Often, BIP starts gradually during treatment, but the
development of BIP up to 6 months after discontinu-
ation of bleomycin therapy has also been reported.20
The clinical diagnosis of BIP is rather hampered by its
resemblance to other conditions often encountered in
cancer patients, such as pneumonia, pulmonary metas-
tases, or lymphangitic carcinoma.
Patients with BIP present initially with a nonpro-
ductive cough, exertional dyspnea, and sometimes
fever. With progressive pneumonitis, dyspnea at rest,
tachypnea, and cyanosis may occur. At physical
examination, fine bibasilar crepitations can be found
initially, progressing to rhonchi and sometimes pleu-
ral rubbing.17
Typical chest radiographic findings are bilateral,
bibasilar infiltrates, sometimes followed by diffuse
interstitial and alveolar infiltrates, and lobar consol-
idation ultimately. However, BIP can also present
with unilateral abnormalities and focal infiltrates.17,21
On CT scanning, bleomycin-induced alterations
may appear earlier than on chest radiographs. In
most patients, small linear and subpleural nodular
lesions in the lung bases are noticed.22
Histologic material, for instance, obtained by
transbronchial biopsies is often not conclusive. There
are no real pathognomic alterations, but the most
characteristic lesions are squamous metaplasia of
bronchiolar epithelium, inflammatory cells infiltrat-
ing into alveoli and alveolar septa, edema plus focal
collagen depositions in these septa, and fibrotic
areas.23,24
Because of the resemblance of the symptoms of
BIP with other diseases, the diagnosis of BIP is often
one of exclusion. Other diseases are often excluded
by culture and Gram-staining of sputum, polymerase
chain reaction on pathogens such as viruses, or
serology or determination of antigens of pathogens
leading to a specific pneumonia. Often these patients
have been treated unsuccessfully with antibiotics
because of the suspicion of pneumonia before the
diagnosis BIP is established. When patients survive
the episode of BIP, they almost always recover
completely with disappearance of symptoms, signs,
and pulmonary function disturbances.17,25
Pathogenesis
The pathogenesis of BIP has been intensively
studied in animals, but data derived from human
studies are scarce. In animals, the first event noted is
endothelial damage of the lung vasculature accom-
panied by edema.26 This is followed by influx of
inflammatory cells such as macrophages, lympho-
cytes, and neutrophils into the lung parenchyma and
subsequently by fibroblasts leading to pulmonary
fibrosis.26 Studies in patients who developed clini-
cally evident BIP showed that alterations in lung
function assessments and chest radiography abnor-
malities are reversible in time,17,25 suggesting that
the pulmonary changes due to bleomycin can be
reversible, probably before the process of fibrosis
starts definitely.
The mechanism of the endothelial damage, the
primary event in the development of BIP, is not
exactly known, but evidence is mounting that the
induction of cytokines and free radicals is involved.
These cytokines and free radicals can damage endo-
thelial cells. Furthermore, the induced cytokines
activate lymphocytes and upregulate adhesion mol-
ecules on endothelial cells, enabling the adhesion of
activated inflammatory cells to the endothelium, the
first step required for influx of these cells into the
interstitium.27 The adhered lymphocytes also con-
tribute to the endothelial damage by inducing apo-
ptosis.28,29 After bleomycin exposure, increased ex-
pression of Fas messenger RNA in pulmonary
endothelial cells and upregulation of its ligand, FasL,
on lymphocytes resulting in apoptosis of the endo-
thelial cells have been described.28 The progression
of BIP could be prevented by pretreatment with
soluble Fas antigen and anti-FasL-antibodies dem-
onstrating the important role of this system.29
One of the primary sources of the cytokines
involved in BIP is the macrophage. In vitro, bleomy-
cin activates human alveolar macrophages that sub-
sequently produce cytokines such as tumor necrosis
factor (TNF)-a and interleukin (IL)-1b.30 In ani-
mals, several studies31–34 have shown significant in-
creases in protein or messenger RNA of TNF-a and
IL-1b in lungs after systemic or intratracheal admin-
istration of bleomycin. In humans, TNF-a is also
induced by bleomycin. A significant rise in TNF-a
plasma levels has been described 3 h, 4.5 h, and 24 h
after administration of bleomycin in testicular cancer
patients.35 Animal studies underlining the important
role of these cytokines in the development of BIP
showed that the development of BIP can be pre-
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vented by the administration of antibodies against
TNF-a34 or by IL-1–receptor antagonists.36
The free radicals that contribute to the endothelial
damage37 are produced by bleomycin directly after
oxidation of the bleomycin-Fe (II) complex3–5 and by
activated polymorphonuclear leukocytes.38 The im-
portance of iron and free radicals in the pathogenesis
of BIP is shown by prevention of BIP by dexrazox-
ane39 or amifostine,40 respectively.
After the damage of the endothelial cells and the
subsequent infiltration of inflammatory cells into the
interstitium, fibroblasts are activated with the ac-
companying deposit of collagen. These fibroblasts
are activated by bleomycin directly41 and indirectly
by bleomycin-induced cytokines such as TNF-a.42,43
In the process of collagen production by fibroblasts,
transforming growth factor (TGF)-b is one of the
central mediators, as has been shown by a study in
animals44 showing the prevention of BIP by antibod-
ies against TGF-b. After administration of bleomycin
to animals, TGF-b has been shown in several cell
types in the lungs, such as in macrophages, fibro-
blasts, endothelial cells, and eosinophils.45 Also, this
TGF-b can be induced by bleomycin46 as well as the
other cytokines induced by bleomycin.47
Pulmonary Function Assessments
Numerous methods such as cell counts in BAL
fluid, gallium lung scanning, angiotensin-converting
enzyme plasma levels, chest radiographs, or CT
scans have been evaluated to detect BIP at an early
stage, in order to avoid the further development of
severe BIP by withholding further treatment with
bleomycin.16 Pulmonary function assessments, how-
ever, seem to be the most proper tool.
Comis et al48 were the first to show a decrease in
the transfer capacity of the lungs for carbon monox-
ide (Tlco) during bleomycin-containing multidrug
chemotherapy. This observation was confirmed by
several subsequent studies.49–51 Based on the histo-
logic changes observed in the lungs after bleomycin
exposure in animals, this decline in Tlco was con-
sidered to be due to bleomycin alone. Several stud-
ies48–50,52–54 have examined whether deterioration of
Tlco was sensitive for detecting BIP and predictive
for the development of clinical significant BIP. Al-
though data from these studies are rather conflicting,
several authors48,55–58 advised stopping further treat-
ment with bleomycin when Tlco decreases . 40%
or 60% of the pretreatment value.
Because bleomycin is almost always used in com-
bination with other drugs that may also affect pul-
monary function assessments, we previously per-
formed a study to test the specificity of pulmonary
function tests for bleomycin-induced pulmonary al-
terations.59 Pulmonary function assessments were
carried out in 54 patients with disseminated testicu-
lar cancer randomized to treatment with 360 mg of
bleomycin, etoposide, and cisplatin (BEP) or with
etoposide and cisplatin (EP) only. During treatment,
a decline of Tlco was found in both groups, and
only at the end of therapy the Tlco was significantly
decreased in the BEP compared with the EP
group.59 It can be concluded that alterations in Tlco
during bleomycin-containing multidrug chemother-
apy are not a proper tool for monitoring BIP and,
thus, cannot be used for decisions regarding further
bleomycin treatment.
Two other pulmonary function tests, however, the
vital capacity (VC) and the pulmonary capillary blood
volume, showed decreased values only in the pa-
tients treated with BEP, while remaining stable in
the EP patients.59 Therefore, these two parameters
are more specific for bleomycin-induced changes.
The VC has been shown to decrease more in patients
developing BIP.50 Also, the total lung capacity
(TLC), a parameter that, like the VC, reflects
changes in lung volume, has been reported49,60 to
decrease significantly in patients developing BIP
compared with those who did not.
Therefore, combined with clinical symptoms, lung
function assessments reflecting lung volumes such as
VC and TLC can be used for patients suspected of
developing BIP. It has to be kept in mind, however,
that there is no association between pulmonary
symptoms and decline of lung function assess-
ments.57
Risk Factors
Many studies have been performed to identify
risk factors for the development of BIP. However,
most of these studies have used different criteria
for its diagnosis. Furthermore, for establishing
BIP, many studies used lung function assessments
that have been shown later not to be specific for
BIP when bleomycin is used in a multidrug regi-
men. In these circumstances and by these lung
function assessments, pulmonary toxicity of bleo-
mycin cannot be distinguished from pulmonary
effects of other agents used. Therefore, compari-
son between studies is severely hampered, while
others are not suitable for the purpose for which
they were designed. Only studies that use BIP-
specific lung function assessments, clinical symp-
toms or signs, or postmortem data are suitable for
identification of risk factors of BIP.
Some studies61,62 suggest that the route by which
bleomycin is administrated may affect bleomycin-
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induced toxicity. Bleomycin continuously infused
may induce less toxicity than bolus injection.61,62
Decreased toxicity has also been described for IM
administration compared to the IV route. However,
other studies21,63 failed to show a relation between
route of administration and toxicity. Therefore, bleo-
mycin is mostly given IV in 30 to 60 min, enabling
administration in an outpatient setting.
In animals, a linear positive relation between dose
and severity of BIP has been found.64,65 Several
studies11,66,67 suggested a similar relation in humans
as well. For instance, in patients receiving a cumu-
lative dose of , 300 mg of bleomycin, the incidence
of BIP is 3 to 5%, while in patients treated with
. 500 mg, 20% of the patients develop BIP.67
However, this dose-toxicity relationship in humans is
less clear than it is in animals. Fatal BIP has been
described in patients treated with , 100 mg of
bleomycin, while in others receiving . 500 mg, no
pulmonary toxicity occurred.68–70 Recently, Simpson
et al19 described 180 patients treated with bleomycin
and they did not find a significant difference in the
cumulative dose of bleomycin between patients who
died of BIP and those who did not. However,
because of the increased incidence of BIP in patients
treated with high doses, it is generally recommended
to keep the total dose of bleomycin , 400 mg.
Age of the patients is also an established risk factor
for the development of BIP. Elderly patients have an
increased susceptibility to develop BIP, especially
those . 70 years,17,21 but BIP has been reported also
in much younger patients. One study19 described
that the occurrence of fatal BIP increased with each
decade after the age of 30 years. The exact reason for
this increased risk is not known; it may be that
decreased radical scavenging or a physiologic decline
of renal function of elderly is involved.
Several studies71,72 aimed to reveal whether a
smoking history increased the risk for BIP. An
increased risk in smokers is strongly suggested by the
study by Lower et al.72 These authors showed radio-
graphic alterations consistent with BIP in 55% of the
smoking patients receiving bleomycin compared
with 0% of the nonsmokers.72
Bleomycin is mainly excreted by the kidneys, and
deterioration of renal function has been shown to
prolong bleomycin clearance. Crooke et al6 showed
that terminal elimination half-life of bleomycin is not
increased until a creatinine clearance of 25 to 35
mL/min, suggesting increased risk of BIP only in
case of severe renal dysfunction. However, the study
by Hall et al73 showed that bleomycin clearance is
positively correlated with serum creatinine, suggest-
ing enhanced bleomycin-induced effects in lesser
degrees of renal dysfunction already. In accordance
with this, many other studies19,74,75 showed a rela-
tionship between decline of renal function and in-
creased bleomycin lung effects. Because bleomycin
is often combined with nephrotoxic agents such as
cisplatin, special attention should be paid for the
development of BIP in patients with prior or devel-
oping renal dysfunction during therapy.
Radiotherapy exerts its function by the induction
of free radicals, and radiotherapy of the chest is
feared for the development of pulmonary fibrosis.
Theoretically, the combination of radiotherapy and
bleomycin could be a synergistic one. However, the
most recent studies57,76 found only a slightly in-
creased occurrence of pulmonary symptoms in pa-
tients treated with the combination compared to
patients treated with bleomycin or radiotherapy
alone. Pulmonary symptoms are most pronounced
during therapy, while there is no evident increase of
long-term sequelae. For instance, in patients with
Hodgkin’s disease, $ 3 years after treatment with
mediastinal radiotherapy (median dose, 44 Gy) and
bleomycin (median dose, 120 U/m2), 37% of the
patients had a FVC of , 80% predicted compared
with 32% and 19% of the patients treated, respec-
tively, with mediastinal radiotherapy or bleomycin
alone.76 Hirsch et al57 showed that in patients with
Hodgkin’s disease treated with bleomycin-containing
multidrug therapy (median dose, 120 U/m2) followed
by radiotherapy (median dose 36 Gy), a significantly
higher percentage of patients developed pulmonary
symptoms such as cough, shortness of breath, and
oxygen requirement within 6 months after treatment
compared with patients treated with chemotherapy
only (50% vs 21%). However, 15 months after
treatment there were no significant differences be-
tween both groups regarding pulmonary symptoms
or functions.57 It can be concluded that the combi-
nation of bleomycin-containing chemotherapy and
radiation is not paralleled with an excess of toxicity,
but that especially during treatment, physicians must
be beware of the development of pulmonary toxicity.
Because bleomycin is assumed to induce its toxic-
ity partially by the induction of free radicals, the
administration of high inspired oxygen could be
hazardous. In most studies64,77,78 carried out in
animals, such a relation has been shown. For in-
stance, in hamsters treated with bleomycin and 70%
oxygen for 72 h, the mortality was 90% compared
with 15% in those animals that received bleomycin
only.64 In humans, clear data showing an increased
risk of BIP with concomitant oxygen supplementa-
tion are lacking; however, because of the data ob-
tained from animal studies, oxygen supplementation
is discouraged during bleomycin treatment. Because
it is also not clear whether prior bleomycin therapy
increases pulmonary toxicity induced by the admin-
istration of oxygen during surgery, Donat and Levy79
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studied 77 patients with disseminated germ-cell tu-
mors undergoing surgical resection for residual mass
after bleomycin-containing chemotherapy (mean,
6.4 months). These authors did not show a significant
difference in length and dose of administered frac-
tional inspired oxygen between the 58 patients with
no problems and the 19 patients with postoperative
pulmonary problems, such as decreased oxygen sat-
uration, pulmonary edema, or dyspnea, requiring
treatment.79
Because of the important role of bleomycin-in-
duced cytokines in the development of BIP, the
increased application of growth factors in patients
receiving chemotherapy could theoretically be par-
alleled by an increased incidence of BIP. These
growth factors such as granulocyte-colony stimulat-
ing factor (G-CSF) can induce other cytokines in-
volved in the pathogenesis of BIP. Although some
case reports80,81 suggested increased risk of BIP in
patients treated with growth factors such as G-CSF,
one study found no increase of BIP in 29 patients
coadministered G-CSF and bleomycin-containing
chemotherapy compared with 57 patients receiving
bleomycin-containing therapy only.60
Prevention and Treatment of BIP
Probably one of the most efficient ways to prevent
BIP is to lower the total cumulative dose of bleomy-
cin. Therefore, several studies18,82,83 have been per-
formed in good-prognosis germ-cell cancer to estab-
lish the role of bleomycin; these studies showed that
bleomycin could not be omitted completely from
combination chemotherapy. However, Einhorn et
al84 showed that lowering the total dose of bleomycin
from 360 to 270 mg does not reduce efficacy of the
treatment of good-prognosis disseminated testicular
cancer.84 Therefore, 270 mg of bleomycin is consid-
ered to be the total dose in combination chemother-
apy for disseminated good-prognosis germ-cell can-
cer in Europe as well as in the United States.85,86
In case of an unacceptable high risk for the
development of BIP, physicians can consider treat-
ing patients with germ-cell cancer with etoposide,
ifosfamide, and cisplatin instead of with the standard
therapy, BEP. Etoposide, ifosfamide, and cisplatin
have been shown to have an equal efficacy as BEP
but at the costs of increased bone marrow suppres-
sion.87,88
The other malignancy for which bleomycin is often
applied is Hodgkin’s disease. The total cumulative
dose of bleomycin is 120 mg/m2 in many regimens.
Although the main cause of pulmonary toxicity dur-
ing treatment is the applied radiotherapy, in case of
a high risk of BIP, nonbleomycin-containing regi-
mens such as mechlorethamine, vincristine, procar-
bazine, and prednisone89 or procarbazine, melpha-
lan, and vinblastine90 can be used.
In animals, several agents have been successfully
tested for prevention or attenuation of BIP, such as
soluble Fas antigen,28 IL-1–receptor antagonists,36
keratinocyte growth factor,91 cyclosporin92 or anti-
bodies against TNF-a,34 CD3 receptor,93 Fas li-
gand,29 or TGF-b.44 Also, dexrazoxane39 and amifos-
tine,40 which both affect bleomycin-induced free
radicals and which are already clinically applied for
decreasing chemotherapy-induced toxicity, have
been shown to be effective in animals. Drugs that
turned out not to be capable of affecting BIP are
enoxaparin,94 pentoxifylline, and linomide.95 Studies
establishing agents that may prevent BIP in humans
have, however, not been performed yet (to my
knowledge).
When clinical BIP occurs, the most widely applied
agents are corticosteroids in high dosages (pred-
nisone, 60 to 100 mg/d). In animals, the data on the
efficacy of corticosteroids for BIP are rather conflict-
ing.28,96 In humans, several case reports describe
successful treatment of pulmonary symptoms during
bleomycin treatment with corticosteroids. However,
it might be possible that in several of these cases, the
diagnosis was not BIP, but BOOP or eosinophilic
hypersensitivity, both of which are known to react on
treatment with corticosteroids. The study of White
and Stover20 suggests some effects of corticosteroids
in the treatment of BIP. These authors describe 10
patients with clinically evident BIP, 7 of whom were
treated with corticosteroids. Initially, all treated pa-
tients showed clinical and radiographic improve-
ment, while lowering the dose of corticosteroids
resulted in recurrence of symptoms in five of the
seven patients. All three untreated patients died
early, while three of seven of the treated patients
died 12 to 15 months after the beginning of BIP.20
However, besides this study, there are no other
studies supporting the efficacy of corticosteroids in
the treatment of BIP, while randomized studies are
missing.
So, it can be concluded that when pulmonary
symptoms start suddenly during bleomycin treat-
ment and infections are excluded, the administration
of corticosteroids is indicated because of a high risk
of BOOP or eosinophilic hypersensitivity. For pul-
monary symptoms starting more gradually and com-
patible with BIP, there are no convincing data for
corticosteroids. In case of BIP, most important is
that further bleomycin administration is withheld.
When patients survive BIP, the pulmonary symp-
toms and disturbances in function assessment will
almost always normalize in time.17,25
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Conclusion
BIP is a severe and sometimes fatal side effect of
bleomycin therapy. Numerous studies have been
performed to identify methods capable of detecting
BIP at an early preclinical stage. Combined with
clinical signs and symptoms, pulmonary function
tests reflecting lung volume such as TLC and VC are
probably most suitable for this purpose. Identifica-
tion of risk factors has probably resulted in decreased
bleomycin-induced morbidity and mortality, but this
has never been examined (to my knowledge). In-
creased knowledge of the pathogenesis may lead to
agents capable of attenuating or preventing BIP,
such as dexrazoxane, which may even permit higher
bleomycin doses. Until that time, physicians admin-
istrating bleomycin have to be aware of the develop-
ment of BIP, especially in the presence of risk factors
(Table 1).
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